MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis - Top-Institutions - MDSpire

MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis

  • By

  • Gianluca Folco

  • Caterina B. Monti

  • Moreno Zanardo

  • Francesco Silletta

  • Davide Capra

  • Francesco Secchi

  • Francesco Sardanelli

  • October 12, 2023

  • 0 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Cardio-Oncology
    • Cardiac MRI
    • Cancer Therapeutics

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Cardiac Imaging
    • Oncology

  • #3

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Cardiac MRI
    • Oncology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Cardiac Imaging
    • Oncology

  • #5

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Cardiology
    • Cardiac Imaging
    • Oncology

Original Source(s)

MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis

  • by Gianluca Folco, Caterina B. Monti, Moreno Zanardo, Francesco Silletta, Davide Capra, Francesco Secchi, Francesco Sardanelli

  • October 12, 2023

Related Content

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Hybrid deep feature and machine learning framework for classification of thyroid nodules in ultrasound images

A CT-based multi-scale fusion model with SHAP interpretation for preoperative differentiation between lung adenocarcinoma in situ/minimally invasive adenocarcinoma and invasive adenocarcinoma: a multicenter study